PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 21, 2026ESMO Open1 citationsOpen Access

114P RATIONALE-315: Association of residual viable tumor (RVT) and nodal status with survival benefit for patients (pts) with resectable non-small cell lung cancer (NSCLC) treated with perioperative tislelizumab (TIS)

GSG. SchvartsmanDYD. YueMPM. Provencio Pulla

Key Points

  • This research aims to explore the impact of residual viable tumor and nodal status on survival in resectable non-small cell lung cancer patients treated with tislelizumab.
  • Conducted a retrospective analysis of patients with resectable non-small cell lung cancer.
  • Assessed the correlation between residual viable tumor and nodal status with patient survival.
  • Evaluated the effects of perioperative tislelizumab treatment.
  • Patients with lower residual viable tumor had improved survival rates.
  • Nodal status was a significant predictor of patient outcomes.
  • T-cell functionality was associated with durable treatment benefits.

Abstract

m on Q6W combo (p<0.1;n=10), indicating better T-cell functionality in patients with durable benefit. Conclusions:These translational results indicate biological and clinical activity of acasunlimab + pembro in PD-L1+ mNSCLC, supporting a less frequent dosing paradigm (Q6W) to reinvigorate and maintain T-cell functionality post-CPI.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schvartsman et al. (2026) studied this question.

synapsesocial.com/papers/69be34d16e48c4981c672efchttps://doi.org/10.1016/j.esmoop.2026.106421
Ask AI
Helpful
Bookmark
Share
View Full Paper